• Email
  • Like
  • Save
  • Private Content
  • Embed
 

PharmARC SMMA Case Study on Aricept 23 mg - Public Citizen Petition

by

  • 3,331 views

In this new era of patients, caregivers, physicians, pharmacists, companies and others expressing and sharing their thoughts and opinions, it is imperative to understand their perceptions on therapy ...

In this new era of patients, caregivers, physicians, pharmacists, companies and others expressing and sharing their thoughts and opinions, it is imperative to understand their perceptions on therapy areas and various treatment options. Typically, triggers generate series of discussions and comments. In this case, Public Citizen Petition to FDA to ban the 23 mg dose of Aricept has been the trigger. The news generated some buzz on social media platforms, blogs, forums and news websites. The discussions were around various issues concerning efficacy, side effects and cost concerns for Aricept 23 mg.

Accessibility

Categories

Upload Details

Uploaded via SlideShare as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

Cancel

4 Embeds 1,415

http://www.pharmarc.com 1401
http://feeds.feedburner.com 11
http://pharmarc.com 2
http://admin.totalmarketing.com 1

Statistics

Likes
0
Downloads
18
Comments
0
Embed Views
1,415
Views on SlideShare
1,916
Total Views
3,331
Post Comment
Edit your comment

PharmARC SMMA Case Study on Aricept 23 mg - Public Citizen Petition PharmARC SMMA Case Study on Aricept 23 mg - Public Citizen Petition Presentation Transcript